Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIP...
FY'24 ARR guidance lowered to DKK 101m-106m on KYC delays.
Redeye views Xbrane’s announcement of a partner for its Opdivo biosimilar as a positive development ...
Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding ...
Redeye comments on Active Biotech's 2024 rights issue and updates its base case.
Under kvartalet nåddes överenskommelser med majoriteten av obligationsinvesterarna och efter kvartal...
Redeye comments on Embracer's announcment of Asmodee's financial targets and an equity investment of...
Redeye downgrades Nekkar’s outlook on the back of a Q3’24 report that missed our forecast, mainly dr...
Redeye provides a short comment on the recently announced SEK12.
Redeye return with a research update following BioArctic's Q3 report and recent events, including th...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Some positive signs in Germany, but market still weak '25e-'26e EBIT raised by 11-12%, driven by Ger...
Nettoomsättningen för det tredje kvartalet uppgick till 9,7 MEURO (10,3), vilket motsvarade en minsk...
Redeye updates its estimates following CTEK’s Q3 report, which was better than we expected.
Redeye saw a report with sales that were lower than our expectations.
